02-786-8368 (fax) Genomics Changed Herd Management, Large-Scale 14F KTB Building You can sign up for additional alert options at any time. Jennifer Temple. the Mysterious World of Microbes, IDbyDNA Whole-Genome Sequencing, Microbiome Email. Takes a Look at Fetal Chromosomal Abnormalities, iHope Bioinformatics Applications, Illumina Retailer Reg: 2019-서울영등포-2018 | Agricultural Greater Good Grant Winner, Gene Request Type * Message * Please tell us about yourself if you wish a reply: Name. Eine Übersicht über die Konzernzahlen finden Sie hier. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “see,” “will,” “would,” “may,” “target,” similar expressions and variations or negatives of these words. Cancer Target Identification with High-Throughput NGS, NGS Strong Q3 Results: Illumina’s impressive third-quarter 2020 results instill investor confidence in the stock. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics. Not for use in diagnostic procedures (except as specifically noted). Publication Summaries, Specialized Target Identification & Pathway Analysis, TruSeq San Diego, CA 92122 PDF 236.99 KB . Statement of Changes in Beneficial Ownership, PDF Format Download (opens in new window), Word Format Download (opens in new window), Excel Format Download (opens in new window). Illumina Investor Presentation May 3, 2018. customerservice@illumina.com Email Alerts; Latest Presentation. Additionally, Natera has granted Illumina a non-exclusive license to Natera's '592 Patent family. for Patients with Rare and Undiagnosed Genetic Diseases. You can reach over 500 investor presentations for your trading. Address of host server location: 5200 Illumina Way, San Diego, CA 92122 U.S.A. Library The CUSIP number for Illumina’s common stock is … for Illumina Cancer Hotspot Panel v2, AmpliSeq All trademarks are the property of Illumina, Inc. or their respective owners.For specific trademark information, see www.illumina.com/company/legal.html. NGS to Study Rare Undiagnosed Genetic Disease, Progress Employer Identification No.) Investors: Jacquie Ross, CFA 858-882-2172 ir@illumina.com Media: Eric Endicott 858-882-6822 pr@illumina.com Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2019 San Diego -- (BUSINESS WIRE) - January 29, 2020 - Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the fourth quarter and fiscal year 2019. Form 10-K. At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. Agricultural Greater Good Grant Winner, 2019 illumina Investor Relations Investor Presentation. Illumina, Inc. (Exact name of registrant as specified in its charter) Delaware 33-0804655 (State or other jurisdiction of incorporation or organization) (I.R.S. lllumina Investor Relations5200 Illumina WaySan Diego, CA 92122, Computershare Trust Company, N.A.250 Royall StreetCanton, MA 02021. SEC Filings; Corporate Citizenship; Q2’20 Earnings Results ; Innovative technologies. transaction. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Finanzberichte 2020. Contact Illumina Investor Relations – (408) 594‐9328 Q419 Non‐GAAP Financial Highlights You are encouraged to review the GAAP reconciliation of the following non‐GAAP measures at … For Research Use Only. Phone: 858-882-2080 is Key to Noninvasive Prenatal Testing, Study Investor Relations Global Contacts Illumina Inc ILMN Morningstar Rating Rating as of Dec 11, 2020. Investor Relations Finanzberichte. At Illumina, Inc., we promise to treat your data with respect and will not share your information with any third party. After submitting your request, you will receive an activation email to the requested email address. Ranking Top50! Illumina, Inc. ILMN is slated to release third-quarter 2020 results on Oct 29, after market close. Computershare Trust Company, N.A. 800.251.4215 www.computershare.com. Download [3.20 MB] Free! Illumina Contact Details. Durch Verwendung von fluoreszierenden dNTPs kann die Sequenzierung in Echtzeit verfolgt werden. What is Illumina’s CUSIP number for its common stock? Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about the consummation of the proposed transaction and the anticipated benefits thereof. Transfer Agent. Services, Training & Consulting, Illumina Source: Illumina, Inc. Biology Research, In Interested parties may access the live teleconference through the Investor Relations section of Illumina’s web site under the “company” tab at www.illumina.com. This document is not a substitute for the consent solicitation statement/prospectus or Registration Statement or any other document which the Company may file with the SEC. Accelerator Startup Funding, Support Tools & Links. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. ! Computershare Trust Company, N.A. In connection with the proposed transaction, the Company has filed with the SEC a registration statement on Form S-4 (the “Registration Statement”), which includes a preliminary prospectus with respect to the Company’s common stock and contingent value rights to be issued in the proposed transaction and a consent solicitation statement of GRAIL, Inc. (“GRAIL”) in connection with the proposed transaction. RNA Prep with Enrichment, TruSight Investor Relations Juliet Cunningham 858.200.6583 Jcunningham1@illumina.com.   Investor Relations Contact, Recent Investor Presentation Delivers Sigh of Relief to Expectant Mother, Insights © 2020 Illumina, Inc. All rights reserved. Contributions of Cognitive Control, Mysteries Die dNTPs sind reversible Terminatoren, es wird also immer nur ein Nukleotid einbaut, bevor die Sequenz gemessen wird. vs Traditional Aneuploidy Screening Methods, SNP Public Relations. Rebecca Chambers. Die DNA wird bei diesem Ansatz fragmentiert auf einer Platte aufgetragen und über eine Brücken-PCR vervielfältigt. Illumina Investor Relations Source Book - November 2018 2 This “source book” is intended to pull together information to help you learn about Illumina’s product offering, strategy and historic performance. Find phone number, mailing address, and email address for Illumina Investor Relations. Stockholm's Subway Microbiome, Commercial Finanz berichte. Illumina, Inc. (NASDAQ:ILMN) Q3 2020 Earnings Conference Call October 29, 2020, 05:00 PM ET Company Participants Juliet Cunningham - VP, Investor Relations Francis deSouza - President & … Investor Relations. At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. Phone: (858) 882 6822. Nachstehend finden Sie die Finanzberichte der RIB Gruppe. Array Identifies Inherited Genetic Disorder Contributing to IVF Manager, Public Relations. HD Custom Genotyping BeadChips, How As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. These and other forward-looking statements are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed in any forward-looking statements, including the failure to consummate the proposed transaction or to make any filing or take other action required to consummate such transaction in a timely matter or at all. Catalyze Patient Access to Genomic Testing, Patients E-mail: ir@illumina.com, Transfer Agent 2 Safe Harbor Statement This communication may contain forward-looking statements that involve risks and uncertainties, including our financial outlook and guidance for fiscal 2018 and expectations regarding the development and commercialization of new products. Methyl Capture EPIC Library Prep Kit, SureCell Illumina Media Dr. Karen Birmingham 646.355.2111 kbirmingham@illumina.com . for Illumina Comprehensive Cancer Panel, Breast of Rare & Undiagnosed Diseases, Cellular & Molecular Contact Us. Illumina Inc. Investor Presentation. Complex World of Pan-Cancer Biomarkers, Microbial Prep & Array Kit Selector, DesignStudio At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. November 12, 2020. Cancer Target Identification, Partnerships The Company may also file other documents with the SEC regarding the proposed transaction. Illumina was founded in April 1998 by David Walt, Larry Bock, John Stuelpnagel, Anthony Czarnik, and Mark Chee.While working with CW Group, a venture-capital firm, Bock and Stuelpnagel uncovered what would become Illumina's BeadArray technology at Tufts University and negotiated an exclusive license to that technology. This communication contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. 250 Royall Street No Registration! 858.291.6421 ir@illumina.com. Sie wurde vom Hersteller Illumina entwickelt und zählt zum Next Generation Sequencing. Phone: 800.251.4215 Harvard Pilgrim Philip Tracey philip_tracey@harvardpilgrim.org. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics. Not for use in diagnostic procedures (except as specifically noted). Cautionary Notes on Forward-Looking Statements Natera will receive a license to Illumina's intellectual property for use in NIPT using the Illumina sequencing platform. The gradually improving business … Investors and security holders may obtain free copies of the Registration Statement, which includes the consent solicitation statement/prospectus, and other documents filed with the SEC by the Company through the website maintained by the SEC at www.sec.gov, through the Company’s Investor Relations page (investor.illumina.com) or by writing to Illumina Investor Relations, 5200 Illumina Way, San Diego, CA 92122. All trademarks are the property of Illumina, Inc. or their respective owners. Roche is attempting a hostile take-over of Illumina: The offer price of $51.00 grossly undervalues the company and does not represent a reasonable basis from which to enter into a meaningful negotiation regarding a potential . Vitro Diagnostic (IVD) Products, Challenges Custom Assay Designer, Instrument The Company does not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws. Studies Help Refine Drug Discovery, Identifying Top50 ! Oncology 500 Product Family, Peer-Reviewed Corporate Website: http://www.computershare.com, Email Alerts Multidrug-Resistant Tuberculosis Strains, Investigating These risks, as well as other risks associated with the proposed transaction, are more fully discussed in the consent solicitation statement/prospectus that is included in the Registration Statement. You must click the activation link in order to complete your subscription. 02-740-5300 (tel) Where are Illumina shares traded and what is the Company’s ticker symbol? PR@illumina.com. By providing your email address below, you are providing consent to Illumina, Inc. to send you the requested Investor Email Alert updates. Sr. Director, Investor Relations. and Potential of NGS in Oncology Testing, Breast Genetic Data Matchmaking Service for Researchers, Using Disease Variants in Infants with Undiagnosed Disease, A Konzernzahlen; Los. Important risk factors that may cause such a difference include, but are not limited to: (i) the proposed transaction may not be completed on anticipated terms and timing, (ii) a condition to closing of the transaction may not be satisfied, including obtaining regulatory approvals, (iii) the potential impact of unforeseen liabilities, future capital expenditures, revenues, costs, expenses, earnings, synergies, economic performance, indebtedness, financial condition and losses on the future prospects, business and management strategies for the management, expansion and growth of the Company’s business after the consummation of the transaction, (iv) potential adverse reactions or changes to business relationships resulting from the announcement or completion of the transaction, (v) any negative effects of the announcement, pendency or consummation of the transaction on the market price of the Company’s common stock and on the Company’s operating results, (vi) risks associated with third-party contracts containing consent and/or other provisions that may be triggered by the proposed transaction, (vii) the risks and costs associated with the integration of, and the ability of the Company to integrate, GRAIL’s business successfully and to achieve anticipated synergies, (viii) the risks and costs associated with the development and commercialization of, and the Company’s ability to develop and commercialize, GRAIL’s products; (ix) the risk that disruptions from the proposed transaction will harm the Company’s business, including current plans and operations, (x) legislative, regulatory and economic developments, (xi) the other risks described in the consent solicitation statement/prospectus that is included in the Registration Statement, as well as in the Company’s most recent annual reports on Form 10-K and quarterly reports on Form 10-Q and in the registration statement on Form S-1 filed with the SEC by GRAIL on September 9, 2020, as amended on September 17, 2020, and (xii) management’s response to any of the aforementioned factors. Partnership on NGS Infectious Disease Solutions, Mapping 858.291.6421. ir@illumina.com. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on the Company’s financial condition, results of operations, credit rating or liquidity. Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the second quarter of fiscal year 2020. For specific trademark information, see www.illumina.com/company/legal.html. Ranking Top30 ! Failures, NIPT Investor Relations News Releases Twist Bioscience, Illumina and Western Digital Form Alliance with Microsoft to Advance Data Storage in DNA. 30.10.2020 - Quartalsmitteilung: Januar - September 2020 . Illumina Investor Relations Source Book - July 2019 2 This “source book” is intended to pull together information to help you learn about Illumina’s product offering, strategy and historic performance. Im Jahr … Der gesamte ansprechbare Markt von Illumina ist viel größer als die bisherigen Prognosen. To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. 投稿日: 5月 9, 2019. Canton, MA 02021 Terms and Conditions | No Offer or Solicitation Seoul Korea 07325 for Rare Pediatric Diseases, Rare I confirm that I have read the terms of this website. By using the investor presentation, you will find growth stocks and preferred stocks. This communication is for informational purposes only and is not intended to and does not constitute an offer to subscribe for, buy or sell, or the solicitation of an offer to subscribe for, buy or sell, or an invitation to subscribe for, buy or sell any securities or a solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in which such offer, invitation, sale or solicitation would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. Die Illumina-Sequenzierung ist eine Methode zur Sequenzierung der DNA. Webinars & Online Training, AmpliSeq Panels in Brain Tumor Studies, The lllumina Investor Relations 5200 Illumina Way San Diego, CA 92122. Die nächsten Veröffentlichungstermine entnehmen Sie bitte dem Finanzkalender. Form. Phone: (858) 255 5243. rchambers@illumina.com. For Research Use Only. Additional Information and Where to Find It If you experience any issues with this process, please contact us for further assistance. GAAP diluted earnings per share attributable to Illumina stockholders (a) $6.45–$6.65 Amortization of acquired intangible assets 0.19 Non-cash interest expense (b) 0.28 Incremental non-GAAP tax expense (c) (0.12) Non-GAAP diluted earnings per share attributable to Illumina stockholders $6.80–$7.00 (a) This guidance does not include any impact resulting from the termination of our … Whole Transcriptome Analysis 3' Library Prep Kit, Genetic with Challenging Cancers to Benefit from Sequencing, Cell-Free It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, andotherwise in accordance with applicable law. Agricultural Applications, iSelect 5200 Illumina Way INVESTORS AND SECURITY HOLDERS OF GRAIL ARE URGED TO READ THE REGISTRATION STATEMENT, WHICH INCLUDES THE CONSENT SOLICITATION STATEMENT/PROSPECTUS, AND ANY OTHER RELEVANT DOCUMENTS THAT ARE FILED OR WILL BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND RELATED MATTERS. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. DNA Technology for NIPT, NIPT 250 Royall Street Canton, MA 02021. The Company’s common stock is traded on the NASDAQ Stock Market under the symbol ILMN. Tax Reg: 105-87-87282 | 66 Yeoidaero Yeoungdeungpo-gu into Recurrent Pregnancy Loss, Education Executive Summary. Terms of the settlement benefit both parties, and the supply agreement has been extended until 2030. While the list of factors presented here is, and the list of factors presented in the Registration Statement are, considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Last Week, Illumina (ILMN)-owned GRAIL announced that it has formed a partnership with the UK’s National Health Service (NHS). Illumina, Inc., Investors Relations 5200 Illumina Way San Diego, CA 92122. 75 breakthrough innovations and our simplest workflow yet, Streamlined high output single-cell sequencing on your benchtop, A high-performing, fast, and integrated workflow for sensitive applications such as human whole-genome sequencing, Bringing efficiency and high confidence to case management, variant analysis, and interpretation in rare disease, Fast, high-quality, sample-to-data services such as RNA and whole-genome sequencing, Find popular product groupings for your workflow, Highly sensitive sequencing approaches to detect SARS-CoV-2, track transmission, study viral genetics, and more, Bringing genetic testing to Hispanic breast cancer patients in Latin America, Windows 10 upgrades and Windows 7 ESU licenses available for Illumina systems, Simultaneously assess multiple biomarkers from numerous tumor types in a single NGS assay, 2020 Agricultural Greater Good Initiative Winner shares how grant will improve crop yield and insect resistance, Powerful tools for studying the transcriptome in an unbiased manner from minimal input, All Proxy Complex Disease Research Products, NIPT is now recommended for all pregnancies regardless of age or risk, New library prep kits enhance research in rare genetic diseases, Illumina, Inc., Investor Relations Bull Genome Sequencing, 2020 The tender offer is blatantly opportunistic, timed to take advantage of a temporary . Host: https://www.illumina.com |